---
title: "Lunai Bioworks Inc. (LNAI.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LNAI.US.md"
symbol: "LNAI.US"
name: "Lunai Bioworks Inc."
industry: "Biotechnology"
datetime: "2026-05-20T10:05:21.124Z"
locales:
  - [en](https://longbridge.com/en/quote/LNAI.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LNAI.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LNAI.US.md)
---

# Lunai Bioworks Inc. (LNAI.US)

## Company Overview

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.lunaibioworks.com](https://www.lunaibioworks.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: E (0.82)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 368 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -116.58% |  |
| P/B Ratio | -0.95 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9075033.97 |  |
| Revenue | 20942.00 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -325.46% | E |
| Profit Margin | -612568.11% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | -116.58% | E |
| Total Assets YoY | -91.62% | E |
| Net Assets YoY | -110.81% | E |
| Cash Flow Margin | 4.10% | D |
| OCF YoY | 0.00% | D |
| Turnover | 0.00 | E |
| Gearing Ratio | 196.89% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Lunai Bioworks Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-116.58%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-0.95",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "9075033.97",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "20942.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-325.46%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-612568.11%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-116.58%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-91.62%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-110.81%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "4.10%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "196.89%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.07 | 75/386 | - | - | - |
| PB | -0.95 | 479/386 | - | - | - |
| PS (TTM) | 433.34 | 283/386 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LNAI.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LNAI.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LNAI.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LNAI.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**